The Chronic Effects of Beetroot Juice in Hypertensive Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amrita Ahluwalia, Queen Mary University of London
ClinicalTrials.gov Identifier:
NCT01405898
First received: July 28, 2011
Last updated: September 24, 2013
Last verified: September 2013

July 28, 2011
September 24, 2013
January 2010
April 2013   (final data collection date for primary outcome measure)
Blood pressure [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Change in clinic, home, central and ambulatory blood pressure, as well as arterial stiffness (pulse wave velocity)
Plasma nitrite [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Change in plasma nitrite
Complete list of historical versions of study NCT01405898 on ClinicalTrials.gov Archive Site
  • Plasma [nitrite] [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    change in plasma [nitrite]
  • endothelial function [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    as measured by flow-mediated dilatation
  • blood pressure [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    change in clinic, home, central and ambulatory blood pressure, as well as arterial stiffness (pulse wave velocity)
  • endothelial function [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    as measured by flow-mediated dilatation
Not Provided
Not Provided
 
The Chronic Effects of Beetroot Juice in Hypertensive Subjects
The Chronic Effects of Beetroot Juice on Circulating Plasma Nitrate and Nitrite Levels and Blood Pressure in Hypertensive Subjects

We are interested in the effect of diet on blood pressure. Our previous research has shown that beetroot juice lowers blood pressure in healthy people. We now want to see if beetroot juice has this effect in people with high blood pressure. Beetroot juice is naturally rich in nitrate (also found in most other vegetables but particularly in green leafy vegetables). We think that it is the nitrate that lowers the blood pressure.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Hypertension
Dietary Supplement: beetroot juice
Beetroot juice or Nitrate-free beetroot juice, 4 weeks 250ml daily
  • Experimental: Beetroot Juice
    Intervention: Dietary Supplement: beetroot juice
  • Placebo Comparator: Nitrate-free beetroot juice
    Intervention: Dietary Supplement: beetroot juice
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
68
December 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  1. Healthy adult male and females between 18 and 85 years of age, inclusive.
  2. To be eligible, female subjects will be required to state that they are not pregnant, and will not become pregnant during the course of the study.
  3. Body mass index (BMI) between 18 and 40 kg/m2
  4. A signed and dated written informed consent prior to admission to the study
  5. The subject is able to understand and comply with protocol requirements, instructions and protocol--‐stated restrictions.

and either of the following categories of blood pressure

Category 1--‐Pre--‐hypertensive SBP 130--‐139 or DBP 85--‐89 on no antihypertensives and will not commence antihypertensives during the course of the study.

Category 2--‐Grade 1 hypertensive SBP 140--‐159 or DBP 90--‐99 on no anti--‐hypertensives, no target organ damage (TOD), low cardiovascular disease (CVD) risk Category 3--‐Uncontrolled severe resistant (Grade 3) hypertensive with evidence of difficulty treating to target BP (140/85 or 130/80), with satisfactory adherence to at least one antihypertensive, but insufficient efficacy or intolerance of medications. (Category 3 patients may also be on aspirin and/or a stable dose of cholesterol--‐lowering medications e.g statins).

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. History of symptomatic coronary artery disease, stroke, or other known atherosclerotic disease.
  2. History of chronic viral hepatitis (including presence of hepatitis B surface antigen or hepatitis C antibody), or other chronic hepatic disorders.
  3. History of increased liver function tests (ALT, AST) due to acute or chronic liver conditions, 3x above the upper limit of normal or bilirubin 1.5x above the upper limit of normal at screening.
  4. Renal impairment with creatinine clearance (eGFR) of <50 ml/min at screening.
  5. Current poorly controlled diabetes mellitus, defined as HbA1c >10% at Screen.
  6. Subjects with LDLc, >7.5 mmol/l. Fasting TG level >6mmol/l.
  7. History of heart failure defined as NYHA class II --‐ IV or those with known severe LV dysfunction (EF<30%) regardless of symptomatic status
  8. History of malignancy within the past 5 years, other than non--‐melanoma skin cancer.
  9. Current life--‐threatening condition other than vascular disease (e.g., very severe chronic airways disease, HIV positive, life--‐threatening arrhythmias) that may prevent a subject from completing the study.
  10. Alcohol or drug abuse within the past 6 months.
  11. Use of an investigational device or investigational drug within 30 days or 5 half--‐lives (whichever is the longer) preceding the first dose of study medication.
  12. Subjects who will commence or who are likely to commence treatment with non--‐steroidal anti--‐ inflammatory drugs (NSAIDs) (other than aspirin), from screening until study completion.
  13. Any non--‐stable dosing of ongoing medication regimens throughout the study trial.
  14. The subject has a three--‐month prior history of regular alcohol consumption exceeding an average weekly intake of > 28 units (or an average daily intake of greater than 3 units) for males, or an average weekly intake of > 21 units (or an average daily intake of greater than 2 units) for females. 1 unit is equivalent to a half--‐pint (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine; or a positive alcohol breath test at the screening visit
  15. A positive urine test for drugs of abuse (not related to known medications the subject is taking, i.e., codeine for pain management) or alcohol at screening or prior to study medication administration.
  16. Any other subject whom the Investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities, expected study medication noncompliance, or subject's unwillingness to comply with all study--‐related study procedures).
  17. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).
  18. Subjects with any acute infection, or significant trauma (burns, fractures).
  19. Subjects who have donated more than 500 mL of blood within 56 days prior to the study.
Both
18 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01405898
08/H0703/91 Chronic
No
Amrita Ahluwalia, Queen Mary University of London
Queen Mary University of London
Not Provided
Principal Investigator: Amrita Ahluwalia Queen Mary University London
Queen Mary University of London
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP